Skip to main content Back to Top
Advertisement

5/13/2019

Exenatide Extended-Release Suspension for Injection

Reason for the Shortage

    • AstraZeneca has Bydureon BCise available.
    • AstraZeneca has Bydureon Pen available.

Available Products

    • Bydureon BCise subcutaneous suspension for injection, AstraZeneca, 2 mg, 0.85 mL auto-injector, 4 count, NDC 00310-6540-04
    • Bydureon Pen subcutaneous suspension for injection, AstraZeneca, 2 mg, 0.65 mL pen injector, 4 count, NDC 00310-6530-04

Updated

Updated May 13, 2019 by Stephen Andrews, PharmD, Drug Information Specialist. Created March 20, 2019 by Leslie Jensen, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins